BioWorld MedTech

Oct. 4, 2018

V-Wave kicks off enrollment in pivotal study of device for HF

Israeli startup V-Wave Ltd. reported the start of enrollment in a study of a minimally invasive device to treat patients with New York Heart Association (NYHA) class III and ambulatory class IV symptomatic heart failure (HF). Read More

Lungvision launch seen as step towards winning battle against lung cancer

Neovasc heads for U.S. with Reducer, a minimally invasive angina implant

Datascope warning letter cites supplier, design verification issues

Do drug, device companies meet California's boardroom quota of women?

Appointments and advancements

Daily M&A

Financings

Regulatory front

Product briefs

Other news to note

BioWorld MedTech's Orthopedics Extra

Today's news in brief

BioWorld

BioWorld briefs for Jan. 13, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for January 13, 2025

Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal

BioWorld

The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...

Proteomics study explores how protein changes influence disease

BioWorld Science

Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...

Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance

BioWorld

Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...